Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2023

Summary of Assets Measured at Fair Value on Recurring Basis

The following table presents information about our assets that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands):


March 31, 2023	Level 1		Level 2		Level 3		Total
Assets
Money market securities (cash equivalents)		12,759		—		—		12,759
Restricted cash		50		—		—		50
Total assets	$	12,809	$	—	$	—	$	12,809

Summary of Cash Equivalents

Cash equivalents consist of the following (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized		Estimated
March 31, 2023	Cost		Gains		Losses		Fair Value
Money market securities	$	12,759	$	—	$	—	$	12,759
Total cash equivalents	$	12,759	$	—	$	—	$	12,759
Money market securities (restricted cash)		50		—		—		50
Total restricted cash	$	50	$	—	$	—	$	50

Schedule of Aggregate Fair Value of Principal Amount of Convertible Debt

The aggregate fair value of the principal amount of the convertible debt is a Level 2 fair value measurement.


	March 31, 2023						December 31, 2022
	Principal		Carrying		Fair		Principal		Carrying		Fair
	Amount		Value		Value		Amount		Value		Value
December 2021 Convertible Debt	$	15,000	$	16,371	$	17,256	$	15,000	$	16,071	$	16,987

As of March 31, 2023 and December 31, 2022, the Convertible Debt balance was comprised of the following:


	March 31,			December 31,
	2023			2022
Convertible Debt Information
Principal	$	15,000		$	15,000
Transaction Costs		(50	)		(67	)
Accrued paid-in-kind interest		1,421			1,138
		16,371			16,071